CLVS Clovis Oncology Inc.

25.32
+1.14  (+5%)
Previous Close 24.18
Open 24.19
Price To Book 5.72
Market Cap 1334663460
Shares 52,711,827
Volume 1,222,246
Short Ratio
Av. Daily Volume 2,295,611

NewsSee all news

  1. Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference
  2. The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
  3. Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
  4. Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
  5. Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19608456
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606821
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19605866
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19601945
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 19601227

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing. Abstract presented at ASCO June 2018.
Opdivo and Rubraca
Castration-resistant prostate cancer (mCRPC)
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrollment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Approval announced April 6, 2018.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Rociletinib
Mutant EGFR T790M-positive lung cancer
Development discontinued
Lucitanib
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line
Phase 2 initial data presented at ESMO - 44% ORR.
Rucaparib - TRITON2
Castrate-resistant prostate cancer (mCRPC)
Phase 2 ongoing.
Rucaparib - ATLAS
Urothelial carcinoma
ESMO presentation at ESMO October 2018.
Lucitanib
HR+ Her2- metastatic breast cancer

Latest News

  1. Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference
  2. The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
  3. Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
  4. Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
  5. Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
  6. New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, and Expectations for 2019
  7. Clovis Oncology to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26
  8. See what the IHS Markit Score report has to say about Clovis Oncology Inc.
  9. Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe
  10. What's Behind the Biotech ETF Rally to Start 2019?
  11. Clovis Oncology Announces European Commission Authorization of Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer
  12. Immunomedics Gets CRL From FDA for Breast Cancer Candidate
  13. Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table
  14. 3 Biotech Stocks That Soared This Week: Are They Buys?
  15. Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options
  16. Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause
  17. History Says Pump the Brakes on a Clovis Oncology Stock Rally

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19608456
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606821
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19605866
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19601945
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 19601227
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19600873
  7. SC 13G - Statement of acquisition of beneficial ownership by individuals 19592332
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19583010
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19582038
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19542446